Dyal, Leanne

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 829

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

Anand, S. S., Caron, F., Eikelboom, J. W., Bosch, J., Dyal, L., Aboyans, V., Abola, M. T., Branch, K. R. H., Keltai, K., Bhatt, D. L., et al. (2018) · Journal of the American College of Cardiology

Peripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular Diseases

Cited by 466

Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study

Mente, A., Dehghan, M., Rangarajan, S., McQueen, M., Dagenais, G., Wielgosz, A., Lear, S., Li, W., Chen, H., Yi, S., et al. (2017) · The Lancet Diabetes & Endocrinology

Nutritional Studies and DietFatty Acid Research and Health

Cited by 268

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies

Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology

Renin-Angiotensin System StudiesDementia and Cognitive Impairment Research

Cited by 216

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 137

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35